AN2 Therapeutics, Inc.

AN2 Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops new small-molecule therapeutics using its boron chemistry platform. The company's development pipeline includes programs in hematologic diseases, infectious diseases, and oncology. AN2 Therapeutics has three Phase 2 studies anticipated to begin in 2026, two preclinical candidates, and advanced research programs targeting oncology, bone disorders, and infectious diseases. One key product in development is epetraborole, which is being expanded into a Phase 2 proof-of-concept clinical study for adults with phlebotomy-dependent polycythemia vera (PV). PV is a blood cancer where the bone marrow overproduces red blood cells, increasing hematocrit and potentially leading to serious complications like arterial and venous thromboembolic events. Approximately 155,000 people in the U.S. are estimated to be affected by PV. AN2 Therapeutics plans to initiate the Phase 2 trial for epetraborole in India in the third quarter of 2026. This study is expected to include an open-label sentinel cohort, an open-label dose optimization cohort (Part 1), a double-blind, randomized, placebo-controlled cohort (Part 2), and an optional open-label extension cohort (Part 3).